#### 1 Original Research Article

#### 2 Metallo-β-lactamase mediated rapid increase in carbapenem resistance of

3 Pseudomonas aeruginosa

#### 4 List of Authors and Affiliations

- 5 Hasnain Anjum<sup>1\*</sup>, Shomaia Yasmin Mitu<sup>2\*</sup>, Md. Shamsul Arefin<sup>3</sup>, Meftahul Jannat
- <sup>6</sup> Mitu<sup>4</sup>, Md. Sabir Hossain<sup>5</sup>, Salequl Islam<sup>6</sup>, M.A. Karim Rumi<sup>7</sup>, M. Hasibur Rahman<sup>8#</sup>
- Department of Microbiology, Jahangirnagar University, Savar, Dhaka-1342, Bangladesh. Email:
   anjumabir27@gmail.com.
- Department of Microbiology, Jahangirnagar University, Savar, Dhaka-1342, Bangladesh. Email:
   <u>shomaiamitu@gmail.com</u>.
- Department of Microbiology, Jahangirnagar University, Savar, Dhaka-1342, Bangladesh. Email:
   <u>arefin1120@gmail.com</u>.
- Department of Microbiology, Jahangirnagar University, Savar, Dhaka-1342, Bangladesh. Email:
   <u>mitumeftahul1@gmail.com</u>.
- Department of Biochemistry and Molecular Biology, Jahangirnagar University, Savar, Dhaka-1342,
   Bangladesh. Email: <u>sabirhossain@juniv.edu</u>
- Department of Microbiology, Jahangirnagar University, Savar, Dhaka-1342, Bangladesh; Email:
   <u>salequl@juniv.edu</u>.
- Department of Pathology and Laboratory Medicine, University of Kansas Medical Center, Kansas
   City, KS 66160, USA; Email: <u>mrumi@kumc.edu</u>.
- B. Department of Microbiology, Jahangirnagar University, Savar, Dhaka-1342, Bangladesh; Email:
   <u>hasiburku@juniv.edu</u>.
- 23

#### 24 **Corresponding Author:**

25 M. Hasibur Rahman; Professor, Department of Microbiology, Jahangirnagar University, Savar, Dhaka-

- 26 1342, Bangladesh; Email: hasiburku@juniv.edu https://orcid.org/0000-0001-7213-2158
- \*Hasnain Anjum and Shomaia Yasmin Mitu contributed equally to this work. Author order was
   determined in order of increasing seniority.;
- 29
- 30
- 31
- 32
- 33
- 34

#### <sup>35</sup> Metallo-β-lactamase mediated rapid increase in carbapenem resistance of

#### 36 Pseudomonas aeruginosa

Abstract: Antibiotic-resistant Pseudomonas aeruginosa is a common nosocomial pathogen 37 all over the world. We detected the presence of *P. aeruginosa* in 22% (53 out of 238) of 38 the test samples collected from patients with infections including secondary wound 39 infections, abscesses and urinary tract infections admitted to two academic hospitals in 40 Bangladesh. Resistance to carbapenems (imipenem, and meropenem) was present 41 among 30% (16 out of 53) of these clinical P. aeruginosa isolates, which is more than 2-42 fold higher compared to that of previous studies. Such a rapid increase in carbapenem 43 resistance was mediated by metallo-β-lactamase (MBL). Expression of MBL was 44 detected in 90% (14 out of 16) of these resistant isolates. Molecular analyses revealed 45 that the carbapenem-resistant isolates carried at least one of the MBL variants, either 46 bla-VIM or bla-NDM-1. All the bla-NDM-1 positives carried a 0.5 MDa plasmid. ERIC-47 PCR revealed the highly heterogeneous nature of the P. aeruginosa isolates indicating 48 multiple sources of infection within the hospital. However, the majority of XDR isolates 49 belonged to a single cluster of drug-resistant bacterial infections. These findings 50 indicate that Metallo- $\beta$ -lactamase (MBL) mediated resistance to carbapenem in P. 51 aeruginosa poses a serious threat to the spread of infections among hospitalized patients. 52

Keywords: *Pseudomonas aeruginosa;* nosocomial infection; *carbapenem*-resistance,
 metallo-β-lactamase; genetic variants.

55

#### 56 **1. Introduction**

Pseudomonas aeruginosa (P. aeruginosa) is one of the most common pathogens 57 associated with nosocomial infections (1). This Gram-negative bacterium is a member of 58 the infamous ESKAPE group of bacteria, known for their rapidly increasing antibiotic 59 resistance in healthcare facilities (2, 3). The global priority list of emerging antibiotic-60 resistant bacteria recognizes P. aeruginosa as a critical pathogen that requires an in-61 depth study(4). It is commonly associated with wound infections, urinary tract 62 infections (particularly catheter-associated UTIs), ventilator-associated (UTIs) 63 respiratory tract infections (RTI), and cystic fibrosis (1, 5). 64

The carbapenem group of antibiotics (imipenem, meropenem, ertrapenem, and doripenem) is clinically effective against *P. aeruginosa* (5, 6). However, a steep rise in carbapenem resistance has been reported over the last few years (7). Susceptibility to carbapenems is dependent on their entry to bacteria through the outer membrane porin protein OprD (8). Thus, a reduced expression of OprD can lead to carbapenem resistance in *P. aeruginosa* (8). Other mechanisms of carbapenem resistance include decreased permeability of outer membrane porins, increased production of molecular

efflux pumps, acquisition of chromosomal cephalosporinases, and expression of broad-72 especially carbapenemases like metallo-β-lactamases spectrum beta-lactamases, 73 (MBLs)(9). Acquisition of MBLs through horizontal gene transfer has been increasingly 74 identified in Gram-negative isolates from hospitalized patients(10). These enzymes can 75 hydrolyze most of the  $\beta$ -lactams and are not repressed by serine  $\beta$ -lactamase repressors 76 like tazobactam and clavulanates (11). As MBLs depend on bivalent zinc ions for the 77 hydrolysis of  $\beta$ -lactam antibiotics, they are inactivated by metal chelators like 78 EDTA(12). 79

The origins of MBLs remain unclear; it is most likely transferred from 80 environmental bacteria like Enterobacteriaceae (13). The genes encoding MBLs are mainly 81 spread through mobile genetic elements like integrons residing on plasmids or bacterial 82 genomic DNA (13, 14). The majority of the MBLs belong to subclass B1 (15, 16) and the 3 83 most common MBLs, namely IMP (imipenemase), VIM (Verona integron-encoded 84 metallo-β-lactamase), and NDM(New Delhi metallo-β-lactamase) are well-known for 85 their epidemiological and clinical importance (12, 13, 17). The bla-VIM was first detected 86 in P. aeruginosa in European countries during the late 1990s, and more than 20 different 87 VIM allotypes have been identified worldwide (13, 18). However, bla-NDM-1, which 88 was detected in K. pneumoniae in 2008, has been widely disseminated among 89 Enterobacteriaceae in India (14). A significant increase in the prevalence of these MBLs 90 has been seen throughout the world, including the United Kingdom and Southeast-91 Asian countries like India, Pakistan, and Bangladesh (14, 19, 20). 92

In this study, we investigated the presence of drug-resistant *P. aeruginosa* infection among hospitalized patients in Dhaka, Bangladesh. We observed that resistance to carbapenems has doubled in the past decade (6). Such a rapid increase in carbapenem resistance was mediated by metallo- $\beta$ -lactamase (MBL). We detected the expression of MBL-variants in carbapenem resistant *P. aeruginosa* isolates and determined the heterogenic nature of the clinical isolates.

99

## 100 2. Materials and Methods

## 101 2.1 Isolation and Characterization of clinical isolates

Clinical samples were collected from patients admitted to two academic hospitals, 102 Enam Medical College Hospital (EMCH) and Gonoshasthaya Samaj Vittik Medical 103 College Hospital (GMCH) located at Savar, Bangladesh. The presence of P. aeruginosa 104 was studied in 238 samples consisting of 115 midstream urine, 69 pus, 21 secondary 105 wound infection swab, 12 urinary catheter swab, 10 burn wounds, 9 blood, and 2 106 tracheal aspirate specimens. Pseudomonas Cetrimide Agar (Scharlab S. L., Spain) was 107 used to determine the colony morphology, fluorescence, and pigment production, 108 followed by conventional biochemical tests according to Bargey's Manual of Systemic 109 Bacteriology for presumptive identification of P. aeruginosa as described previously (41, 110 42). Selected isolates were stored in glycerol broth at -80 °C. 111

112

## 113 2.2 Molecular Identification

Molecular identification was carried out by sequencing 16S rDNA of fourteen representative isolates. DNA templates prepared from the selected isolates were subjected to polymerase chain reaction (PCR) (43). The PCR products were purified using Promega Wizard SV Gel and PCR Clean-up System, USA and sequenced. The identity of the isolates was confirmed by BLAST analysis.

119

#### 120 2.3. Screening of Carbapenem Resistance

<sup>121</sup> To determine the susceptibility of clinical *P. aeruginosa* isolates to carbapenem <sup>122</sup> antibiotics, Kirby Bauer disc diffusion test was used (44), followed by determination of <sup>123</sup> MIC against Imipenem (IMP 10  $\mu$ g) and Meropenem (MPM 10  $\mu$ g). Antibiotic discs <sup>124</sup> were obtained from Oxoid, UK. *P. aeruginosa* PAO1 was used as control. Results were <sup>125</sup> interpreted according to CLSI standards and guidelines [24]. MDR nature of isolates <sup>126</sup> was observed against nine additional antibiotics of six different groups (data not <sup>127</sup> included in this study) and interpreted accordingly (45, 46).

128

## 129 2.4. Phenotypic Detection of MBL Production

To detect the production of MBL, imipenem-resistant isolates were subjected to 130 IMP-EDTA double disc synergistic test. The pure cultures of selected isolates were 131 plated on Mueller-Hinton agar (Oxoid, UK) to prepare bacterial lawn. Two imipenem 132 (IMP 10 µg) disks were placed on prepared lawn by at least 20 mm distance. One of the 133 disks was impregnated with 0.5M EDTA to achieve 750 µg/disk concentrations, which 134 can act on MBL by removing zinc ions from the active site of the enzyme, effectively 135 nullifying its activity. The plates were incubated overnight at 37 °C, and zone diameters 136 for both IMP and IMP-EDTA disks were measured. Isolates exhibiting ≥17 mm 137 inhibition zones with IMP-EDTA disc were considered MBL-positive, while isolates 138 with  $\leq 14$  mm inhibition zones were considered MBL-negative (47). 139

140

## 141 2.5. PCR Detection of MBL

The presence of genes encoding four different variants of MBLs bla-NDM-1, bla-142 SPM, bla-IMP, and bla-VIM were investigated in all isolates exhibiting phenotypic 143 resistance against imipenem. PCR reagents were obtained from Promega, USA and the 144primers were designed according to previous publications (24, 48). The primer as well 145 as annealing temperatures are listed in **Table 1**. For each PCR reaction, 2 µl of prepared 146 bacterial DNA was added to 16 µl of prepared PCR-ready mix containing (1X PCR 147 buffer, 2.5mM MgCl2, 0.25 mM dNTP, 1IU of Taq DNA polymerase, 10 pmol of each 148primer), and deionized water was added to obtain a final volume of 25 µl. The PCR 149 reactions were carried out as indicated in Table 3. The PCR products were visualized 150 using a UV transilluminator after electrophoresis in 1% agarose gel. 151

152

153 2.6. ERIC-PCR for Species Diversity Analysis

To observe the diversity among the *P. aeruginosa* isolates, ERIC-PCR (Enterobacterial Repetitive Intergenic Consensus- Polymerase Chain Reaction) was performed using the primer sequence mentioned elsewhere (49). PCR products were separated on 2% agarose gel and visualized under a UV transilluminator. The cluster analysis was conducted by using DendroUPGMA (21, 50).

159

## 160 2.7. Plasmid Extraction

Plasmids from carbapenem-resistant *P. aeruginosa* isolates were extracted according to the modified hot alkaline lysis method by Kado and Liu (51). Extracted plasmids were electrophoresed in 0.7% agarose gel with ethidium bromide (0.5 mg/mL) and visualized under a UV transilluminator. Reference strains of *E. coli* K-12 V517 and PDK9 were used as control strains for the extraction method and plasmid size marker (52, 53).

166

167 2.8. Statistical Analysis

A validated questionnaire was used for data collection. Collected data were verified
 and analyzed by using IBM SPSS Statistics Data Editor (Version 21) and STATA 15.

170

## 171 **3. Results**

## 172 3.1.Isolation and identification of P. aeruginosa

A total of 238 clinical samples were collected from the patients admitted into two 173 academic hospitals in Savar City, at the outskirts of Dhaka, the capital of Bangladesh. 174 Most of clinical samples were collected from patients with UTI, followed by secondary 175 wound infections and abscesses (Table 1). The samples were tested for the presence of 176 P. aeruginosa and 53 (~22%) showed growth on selective cetrimide agar, which were 177 further characterized through standard biochemical tests. Identification of the clinical 178 isolates was confirmed by PCR-based 16SrDNA sequence analyses, which showed a 95 179 to 99% identity to *P. aeruginosa* sequence (e-value ≤0). We detected that wound 180 infections were more frequently positive for *P. aeruginosa* compared to other infections. 181

182183 3.2. Carbapenem resistance in clinical P. aeruginosa isolates

All 53 isolates of *P. aeruginosa* were tested for susceptibility to carbapenem 184 (imipenem and meropenem) using a disk-diffusion method followed by minimum 185 inhibitory concentration (MIC) assays. Out of 53 isolates, 16 (30%) were resistant to both 186 imipenem and meropenem. However, the antibiotic tolerance levels varied widely in 187 the MIC assay. While 50% (8/16) of carbapenem-resistant isolates showed a moderate 188 resistance (8  $\mu$ g/ml), the other 50% isolates had a much higher resistance level ( $\geq$ 16 to 189 128 µg/ml). Among the 16 carbapenem-resistant P. aeruginosa isolates, 6 were from 190 GMCH (38%), while the rest 10 (62%) were from the EMCH (Table 1). Antibiogram 191 profile identified 12 isolates as multidrug resistant (MDR), and another 2 isolates as 192

extensively drug resistant (XDR). Moreover, uniform resistance against third generation
 cephalosporins like ceftriaxone and cefotaxime and significantly lower susceptibility to
 important antibiotics like azithromycin and tetracycline was observed, which is
 alarmingly higher than previous regional reports.

197

## 198 3.3. Detection of MBL in P. aeruginosa isolates

All of the 16 imipenem-resistant *P. aeruginosa* isolates were subjected to enzymatic 199 activity and PCR based genotypic detection of MBL variants. Of the 16 isolates, 14 200 (~88%) were positive for MBL activity in an imipenem-EDTA double-disk synergistic 201 test. PCR-based detection of the MBL variants, bla-VIM, bla-NDM1, bla-IMP, and bla-202 SPM, showed that 10 out of the 16 (~63%)resistant isolates carried at least one. While 203 bla-VIM was detected in 7 out of 16 isolates (44%), bla-NDM-1 was detected in 3 isolates 204 (19.75%) (Figure 1). We did not detect any of MBL variants, bla-VIM, bla-NDM1, bla-205 IMP, and *bla*-SPM in other 6 isolates. Moreover, none of the isolates were multiple MBL 206 genes carrier (Table 3). 207

208

## 209 3.4. Detection of plasmids in MBL positive isolates

Plasmid extraction and gel electrophoresis detected the presence of plasmids in 7 out of the 16 (43%) MBL-positive isolates. Among 7 *bla*-VIM positive isolates, 4 carried a plasmid of 1.2 MDa, while the other 3 isolates did not carry any plamid. In constrast all 3 of the *bla*-NDM1 positive *P. aeruginosa* isolates carried a plasmid of 0.5 MDa (**Table 3**).

214

## 215 3.5. ERIC-PCR and cluster analysis

Enterobacterial Repetitive Intergenic Consensus- Polymerase Chain Reaction 216 (ERIC-PCR) was performed to determine the possible epidemiological relationships 217 among the clinical P. aeruginosa isolates (21). Our results revealed distinct patterns of 218 DNA, indicating species diversity among carbapenem-resistant P. aeruginosa isolates. 219 Highly heterogeneous results indicated that the isolates did not share significant genetic 220 relatedness. Phylogenetic cluster analysis based on unweighted pair group method with 221 arithmetic mean (UPGMA) exhibited the presence of three distinct clusters I-III (Figure 222 2). The majority of the XDR isolates belonged to cluster III, while cluster I and II were 223 composed of MDR isolates. 224

225

## **4. Discussion**

Rapid development of antibiotic-resistance in Gram-negative bacteria including *P. aeruginosa* has become a major public health concern all over the world (2, 3). There is an alarming increase in MDR, XDR, and PDR isolates of *P. aeruginosa* (22, 23). In this study, we also observed frequent occurances of MDR among the *P. aeruginosa* isolates in Bangladesh. Remarkably, one in every three isolates was resistant to carbapenems.

While the interquartile range (IQR) of imipenem resistance found in a systematic review covering studies during 2004 to 2018 was 13.5%, we detected a huge increase to 30%(6).

Our results indicate that the rapid increase in imipenem resistance among P. 234 aeruginosa clinical isolates in Bangladesh is mediated by MBLs. About 88% of the 235 resistant isolates were positive for MBL production. The MBL-positive isolates also 236 showed an elevated level of MIC values of imipenem and meropenem. Resistance to 237 carbapenems is often associated with the acquisition and expression of the MBLs, which 238 includes bla-IMP, bla-VIM, bla-GIM, bla-SPM, bla-NDM and bla-SIM genes (24). In this 239 study 71% of the carbapenem-resistant isolates were found to carry variants of MBL 240 genes. While the majority (7/16; 44%) of the isolates carried bla-VIM, only 19% (3/16) 241 carried *bla*-NDM-1. The current investigation shows a much higher prevalence of MBL 242 genes among P. aeruginosa isolates compared to similar studies conducted in India 243 (12%), Pakistan (18%), China (55%), Iran (40%), and Nigeria (17%)(25-28). Moreover, it 244 needs to be noted that we investigated the presence of only four variants (bla-IMP, bla-245 VIM, bla-SPM, and bla-NDM-1). Therefore, we cannot exclude the presence of other 246 MBL variants in remaining 29% of the isolates. 247

In this study, *bla*-VIM variant was found to be the most prevalent among the MBL genes tested (7/16, 44%). Dissemination of novel variants of *bla*-VIM is commonly mediated by class I integrons like *In58* and *In59* gene cassettes (29, 30). Plasmids carrying class I integrons possess strong dissemination potential (31, 32). However, several of the *bla*-VIM carrier isolates (3/7, 42%) in our study did not carry any plasmid, implying that these isolates may have integrons in their chromosomal DNA.

In this study, the presence of *bla*-NDM-1 was detected among 3 of 16 carbapenem-254 resistant isolates. Classically bla-NDM-1 encoding gene is also plasmid-borne, which 255 has been found to be disseminated through the members of the Enterobacteriaceae and 256 Pseudomonaceae family (32, 33). Transmission of bla-NDM-1 has been also reported in 257 Acinetobacter baumanii by transposon Tn125 (34, 35). It has been shown that bla-NDM-1 258 gene can be carried on plasmids of diverse sizes with incompatibility types that allow 259 interspecies, intergenus, and interfamily transfer (36). In this study, we observed the 260 presence of a 0.5 MDa plasmid in *P. aeruginosa* isolates that carried the *bla*-NDM-1 gene. 261 Remarkably, all bla-NDM-1 carriers were isolated from UTI and catheter-associated 262 infections. 263

We employed ERIC-PCR for molecular typing of genetic relatedness among the *P*. 264 aeruginosa isolates. ERIC-PCR revealed that the carbapenem-resistant P. aeruginosa 265 isolates were distributed in three distinct clusters, with the majority belonging to cluster 266 III. Overall analyses of our ERIC-PCR data indicated a heterogeneous nature of P. 267 aeruginosa isolates and possible independent sources of dissemination. Several previous 268 studies also reported similar heterogenous nature of P. aeruginosa isolates (26, 37). 269 However, the XDR isolates found in this study were all grouped in cluster III in ERIC-270 PCR analyses. 271

Our test samples were collected from two academic hospitals. Interestingly, both 272 carbapenem resistance and the presence of MBL pattern was different between the two 273 hospitals. Although 35% (6/17) of the P. aeruginosa from GMCH were carbapenem 274 resistant, 2 were phenotypically MBL negative and none were positive for the presence 275 of MBL variants tested. In contrast, 28% (10/36) of the P. aeruginosa from EMCH were 276 carbapenem resistant, but all the isolates carried MBL genes. Compared to GMCH, 277 EMCH is a larger, tertiary care hospital that admits more patients for a longer period, 278 which might establish a favorable niche for dissemination of MBL genes among 279 nosocomial agents like P. aeruginosa. Previous studies also suggested that larger number 280 of patients may harbor frequent source of drug resistant bacterial infections and 281 prolonged hospitalization may increase the risk of acquisition of drug resistance 282 elements through horizontal gene transfer (38, 39). A recent study in Bangladesh also 283 demonstrated that hospital environment is a major reservoir for carbapenem-resistant 284 *P. aeruginosa* with MBL carriage (40). 285

Indiscriminate use of therapeutically important antibiotics is presumed to be the major cause of antibiotic resistance and the transmission of such resistant pathogens is more likely among hospitalized patients, especially those who need prolonged stay. Horizontal transfer of antibiotic resistance determinants further complicates the control strategies. Our results suggest that rapid screening by molecular techniques like ERIC-PCR may help track multidrug-resistant *P. aeruginosa* outbreaks in hospitals and develop point-of-care surveillance.

293

#### 294 5. Conclusions

The emerging threat of ever-increasing antibiotic resistance among *P. aeruginosa* of 295 clinical origin is a major concern for the treatment of nosocomial infections caused by 296 the pathogen. The magnitude of multidrug resistance and the presence of MBL variants 297 in clinical settings reported in this study require immediate attention to improve 298 infection control and prevention programs. This study also suspects the hospital 299 environment to facilitate the horizontal transfer of resistance elements like MBL genes. 300 Implementation of antibiotic stewardship policy alongside proper infection control now 301 has become a public health emergency to combat the emerging threat of superbugs in 302 healthcare settings of developing countries like Bangladesh. 303

304

#### 305 **6.** *Ethics statement*

306

This study was approved by the Ethics and Research Review Committee of the Jahangirnagar University Faculty of Biological Sciences [Ref No: BBEC, JU/M 2020 (1)4]. Written informed consent was obtained from patients for sample collection, and their personal identities along with other information were anonymized.

Author Contributions: All authors made a significant contribution to the work reported. M.H.R. conceptualized and supervised the study. H.A., S.Y.M., M.S.A, and M.J.M. collected the clinical samples and conducted laboratory experiments. H.A. and S.Y.M. also analyzed the data and prepared the manuscript. M.S.H. and S.I. made significant contributions to the study design and M.A.K.R. edited the manuscript. The authors agree and approve the content of the final version of the manuscript.

Funding: M. H.R. received funding support from the Grants for Advanced Research in Education (GARE), the Ministry of Education, Bangladesh (Award ID: bs-37.20.0000.004.033.020.2016.673).

Acknowledgments: The authors would like to thank the laboratory personnel of Enam Medical College Hospital and Gonoshasthaya Medical College Hospital, Dhaka, Bangladesh, for their support in the collection of the clinical samples.

323 **Conflicts of Interest:** The authors declare that they have no conflict of interest.

324

#### 325 **References**

326

 Kollef MH, Shorr A, Tabak YP, Gupta V, Liu LZ, Johannes RS. Epidemiology and outcomes of health-careassociated pneumonia: results from a large US database of culture-positive pneumonia. Chest. 2005;128(6):3854-62. doi: 10.1378/chest.128.6.3854. PubMed PMID: 16354854.

Boucher HW, Talbot GH, Bradley JS, Edwards JE, Gilbert D, Rice LB, et al. Bad bugs, no drugs: no ESKAPE!
 An update from the Infectious Diseases Society of America. Clin Infect Dis. 2009;48(1):1-12. doi: 10.1086/595011.
 PubMed PMID: 19035777.

Rice LB. Progress and challenges in implementing the research on ESKAPE pathogens. Infect Control Hosp
 Epidemiol. 2010;31 Suppl 1:S7-10. doi: 10.1086/655995. PubMed PMID: 20929376.

Mancuso G, Midiri A, Gerace E, Biondo C. Bacterial Antibiotic Resistance: The Most Critical Pathogens.
 Pathogens. 2021;10(10). Epub 20211012. doi: 10.3390/pathogens10101310. PubMed PMID: 34684258; PubMed Central
 PMCID: PMC8541462.

Mittal R, Aggarwal S, Sharma S, Chhibber S, Harjai K. Urinary tract infections caused by Pseudomonas
 aeruginosa: a minireview. J Infect Public Health. 2009;2(3):101-11. Epub 20090919. doi: 10.1016/j.jiph.2009.08.003.
 PubMed PMID: 20701869.

Ahmed I, Rabbi MB, Sultana S. Antibiotic resistance in Bangladesh: A systematic review. Int J Infect Dis.
 2019;80:54-61. Epub 20190110. doi: 10.1016/j.ijid.2018.12.017. PubMed PMID: 30634043.

J. Lodise TP, Bassetti M, Ferrer R, Naas T, Niki Y, Paterson DL, et al. All-cause mortality rates in adults with
carbapenem-resistant Gram-negative bacterial infections: a comprehensive review of pathogen-focused, prospective,
randomized, interventional clinical studies. Expert Rev Anti Infect Ther. 2022;20(5):707-19. Epub 20220112. doi:
10.1080/14787210.2022.2020099. PubMed PMID: 34937518.

Beig M, Taheri M, Arabestani MR. Expression of MexAB-OprM efflux pump and OprD porin in
 carbapenemase producing Pseudomonas aeruginosa clinical isolates. Gene Reports. 2020;20:100744. doi:
 <u>https://doi.org/10.1016/j.genrep.2020.100744</u>.

Rostami S, Farajzadeh Sheikh A, Shoja S, Farahani A, Tabatabaiefar MA, Jolodar A, et al. Investigating of
 four main carbapenem-resistance mechanisms in high-level carbapenem resistant Pseudomonas aeruginosa isolated
 from burn patients. J Chin Med Assoc. 2018;81(2):127-32. Epub 20171009. doi: 10.1016/j.jcma.2017.08.016. PubMed
 PMID: 29033110.

Deshmukh DG, Damle AS, Bajaj JK, Bhakre JB, Patwardhan NS. Metallo-β-lactamase-producing clinical
isolates from patients of a tertiary care hospital. J Lab Physicians. 2011;3(2):93-7. doi: 10.4103/0974-2727.86841.
PubMed PMID: 22219562; PubMed Central PMCID: PMC3249725.

Emeraud C, Escaut L, Boucly A, Fortineau N, Bonnin RA, Naas T, et al. Aztreonam plus Clavulanate,
Tazobactam, or Avibactam for Treatment of Infections Caused by Metallo-β-Lactamase-Producing Gram-Negative
Bacteria. Antimicrob Agents Chemother. 2019;63(5). Epub 20190425. doi: 10.1128/aac.00010-19. PubMed PMID:
30858212; PubMed Central PMCID: PMC6496057.

Walsh TR, Toleman MA, Poirel L, Nordmann P. Metallo-beta-lactamases: the quiet before the storm? Clin
 Microbiol Rev. 2005;18(2):306-25. doi: 10.1128/cmr.18.2.306-325.2005. PubMed PMID: 15831827; PubMed Central
 PMCID: PMC1082798.

- 13. Cornaglia G, Giamarellou H, Rossolini GM. Metallo-β-lactamases: a last frontier for β-lactams? Lancet Infect
   Dis. 2011;11(5):381-93. doi: 10.1016/s1473-3099(11)70056-1. PubMed PMID: 21530894.
- Kumarasamy KK, Toleman MA, Walsh TR, Bagaria J, Butt F, Balakrishnan R, et al. Emergence of a new
  antibiotic resistance mechanism in India, Pakistan, and the UK: a molecular, biological, and epidemiological study.
  Lancet Infect Dis. 2010;10(9):597-602. Epub 20100810. doi: 10.1016/s1473-3099(10)70143-2. PubMed PMID: 20705517;
  PubMed Central PMCID: PMC2933358.
- Bush K. The ABCD's of β-lactamase nomenclature. J Infect Chemother. 2013;19(4):549-59. Epub 20130705.
   doi: 10.1007/s10156-013-0640-7. PubMed PMID: 23828655.
- Mojica MF, Bonomo RA, Fast W. B1-Metallo-β-Lactamases: Where Do We Stand? Curr Drug Targets.
   2016;17(9):1029-50. doi: 10.2174/1389450116666151001105622. PubMed PMID: 26424398; PubMed Central PMCID:
   PMC4814356.
- Queenan AM, Bush K. Carbapenemases: the versatile beta-lactamases. Clin Microbiol Rev. 2007;20(3):440-58,
  table of contents. doi: 10.1128/cmr.00001-07. PubMed PMID: 17630334; PubMed Central PMCID: PMC1932750.
- 18. Lauretti L, Riccio ML, Mazzariol A, Cornaglia G, Amicosante G, Fontana R, et al. Cloning and
  characterization of blaVIM, a new integron-borne metallo-beta-lactamase gene from a Pseudomonas aeruginosa
  clinical isolate. Antimicrob Agents Chemother. 1999;43(7):1584-90. doi: 10.1128/aac.43.7.1584. PubMed PMID:
  10390207; PubMed Central PMCID: PMC89328.
- 19. Khan AU, Maryam L, Zarrilli R. Structure, Genetics and Worldwide Spread of New Delhi Metallo-βlactamase (NDM): a threat to public health. BMC Microbiol. 2017;17(1):101. Epub 20170427. doi: 10.1186/s12866-0171012-8. PubMed PMID: 28449650; PubMed Central PMCID: PMC5408368.
- Urmi UL, Nahar S, Rana M, Sultana F, Jahan N, Hossain B, et al. Genotypic to Phenotypic Resistance
  Discrepancies Identified Involving β-Lactamase Genes, blaKPC, blaIMP, blaNDM-1, and blaVIM in Uropathogenic
  Klebsiella pneumoniae. Infect Drug Resist. 2020;13:2863-75. Epub 20200818. doi: 10.2147/idr.S262493. PubMed PMID:
  32903880; PubMed Central PMCID: PMC7445497.
- Ranjbar R, Tabatabaee A, Behzadi P, Kheiri R. Enterobacterial Repetitive Intergenic Consensus Polymerase
   Chain Reaction (ERIC-PCR) Genotyping of Escherichia coli Strains Isolated from Different Animal Stool Specimens.
   Iran J Pathol. 2017;12(1):25-34. Epub 20161229. PubMed PMID: 29760750; PubMed Central PMCID: PMC5938721.
- Micek ST, Wunderink RG, Kollef MH, Chen C, Rello J, Chastre J, et al. An international multicenter
  retrospective study of Pseudomonas aeruginosa nosocomial pneumonia: impact of multidrug resistance. Crit Care.
  2015;19(1):219. Epub 20150506. doi: 10.1186/s13054-015-0926-5. PubMed PMID: 25944081; PubMed Central PMCID:
  PMC4446947.
- Palavutitotai N, Jitmuang A, Tongsai S, Kiratisin P, Angkasekwinai N. Epidemiology and risk factors of
   extensively drug-resistant Pseudomonas aeruginosa infections. PLoS One. 2018;13(2):e0193431. Epub 20180222. doi:
   10.1371/journal.pone.0193431. PubMed PMID: 29470531; PubMed Central PMCID: PMC5823452.
- 24. Ellington MJ, Kistler J, Livermore DM, Woodford N. Multiplex PCR for rapid detection of genes encoding
  acquired metallo-beta-lactamases. J Antimicrob Chemother. 2007;59(2):321-2. Epub 20061221. doi: 10.1093/jac/dkl481.
  PubMed PMID: 17185300.
- 401 25. Mohanam L, Menon T. Coexistence of metallo-beta-lactamase-encoding genes in Pseudomonas aeruginosa.
  402 Indian J Med Res. 2017;146(Supplement):S46-s52. doi: 10.4103/ijmr.IJMR\_29\_16. PubMed PMID: 29205195; PubMed
  403 Central PMCID: PMC5735570.
- Saleem S, Bokhari H. Resistance profile of genetically distinct clinical Pseudomonas aeruginosa isolates from
  public hospitals in central Pakistan. J Infect Public Health. 2020;13(4):598-605. Epub 20190926. doi:
  10.1016/j.jiph.2019.08.019. PubMed PMID: 31564530.

407 27. Olaniran OB, Adeleke OE, Donia A, Shahid R, Bokhari H. Incidence and Molecular Characterization of
408 Carbapenemase Genes in Association with Multidrug-Resistant Clinical Isolates of Pseudomonas aeruginosa from
409 Tertiary Healthcare Facilities in Southwest Nigeria. Curr Microbiol. 2021;79(1):27. Epub 20211214. doi:
410 10.1007/s00284-021-02706-3. PubMed PMID: 34905085.

28. Namaei MH, Yousefi M, Askari P, Roshanravan B, Hashemi A, Rezaei Y. High prevalence of multidrugresistant non-fermentative Gram-negative bacilli harboring bla (IMP-1) and bla (VIM-1) metallo-beta-lactamase genes
in Birjand, south-east Iran. Iran J Microbiol. 2021;13(4):470-9. doi: 10.18502/ijm.v13i4.6971. PubMed PMID: 34557275;
PubMed Central PMCID: PMC8421574.

29. Botelho J, Grosso F, Quinteira S, Brilhante M, Ramos H, Peixe L. Two decades of blaVIM-2-producing
Pseudomonas aeruginosa dissemination: an interplay between mobile genetic elements and successful clones. J
Antimicrob Chemother. 2018;73(4):873-82. doi: 10.1093/jac/dkx517. PubMed PMID: 29373674.

30. Siarkou VI, Vitti D, Protonotariou E, Ikonomidis A, Sofianou D. Molecular epidemiology of outbreak-related
pseudomonas aeruginosa strains carrying the novel variant blaVIM-17 metallo-beta-lactamase gene. Antimicrob
Agents Chemother. 2009;53(4):1325-30. Epub 20090121. doi: 10.1128/aac.01230-08. PubMed PMID: 19164147; PubMed
Central PMCID: PMC2663106.

422 31. Lombardi G, Luzzaro F, Docquier JD, Riccio ML, Perilli M, Colì A, et al. Nosocomial infections caused by
423 multidrug-resistant isolates of pseudomonas putida producing VIM-1 metallo-beta-lactamase. J Clin Microbiol.
424 2002;40(11):4051-5. doi: 10.1128/jcm.40.11.4051-4055.2002. PubMed PMID: 12409373; PubMed Central PMCID:
425 PMC139695.

426 32. Poirel L, Naas T, Nicolas D, Collet L, Bellais S, Cavallo JD, et al. Characterization of VIM-2, a carbapenemhydrolyzing metallo-beta-lactamase and its plasmid- and integron-borne gene from a Pseudomonas aeruginosa
clinical isolate in France. Antimicrob Agents Chemother. 2000;44(4):891-7. doi: 10.1128/aac.44.4.891-897.2000. PubMed
PMID: 10722487; PubMed Central PMCID: PMC89788.

33. Walsh TR, Weeks J, Livermore DM, Toleman MA. Dissemination of NDM-1 positive bacteria in the New
Delhi environment and its implications for human health: an environmental point prevalence study. Lancet Infect
Dis. 2011;11(5):355-62. Epub 20110407. doi: 10.1016/s1473-3099(11)70059-7. PubMed PMID: 21478057.

433 34. Pfeifer Y, Wilharm G, Zander E, Wichelhaus TA, Göttig S, Hunfeld KP, et al. Molecular characterization of
434 blaNDM-1 in an Acinetobacter baumannii strain isolated in Germany in 2007. J Antimicrob Chemother.
435 2011;66(9):1998-2001. Epub 20110621. doi: 10.1093/jac/dkr256. PubMed PMID: 21693460.

436 35. Poirel L, Bonnin RA, Boulanger A, Schrenzel J, Kaase M, Nordmann P. Tn125-related acquisition of
437 blaNDM-like genes in Acinetobacter baumannii. Antimicrob Agents Chemother. 2012;56(2):1087-9. Epub 20111205.
438 doi: 10.1128/aac.05620-11. PubMed PMID: 22143526; PubMed Central PMCID: PMC3264265.

 439
 36.
 Carattoli A. Plasmids and the spread of resistance. Int J Med Microbiol. 2013;303(6-7):298-304. Epub

 440
 20130314. doi: 10.1016/j.ijmm.2013.02.001. PubMed PMID: 23499304.

441 37. Hematzadeh A, Haghkhah M. Biotyping of isolates of Pseudomonas aeruginosa isolated from human
442 infections by RAPD and ERIC-PCR. Heliyon. 2021;7(9):e07967. Epub 20210908. doi: 10.1016/j.heliyon.2021.e07967.
443 PubMed PMID: 34604557; PubMed Central PMCID: PMC8473555.

38. Stanton RA, Campbell D, McAllister GA, Breaker E, Adamczyk M, Daniels JB, et al. Whole-Genome
Sequencing Reveals Diversity of Carbapenem-Resistant Pseudomonas aeruginosa Collected through CDC's
Emerging Infections Program, United States, 2016-2018. Antimicrob Agents Chemother. 2022;66(9):e0049622. Epub
20220906. doi: 10.1128/aac.00496-22. PubMed PMID: 36066241; PubMed Central PMCID: PMC9487505.

Aslam B, Wang W, Arshad MI, Khurshid M, Muzammil S, Rasool MH, et al. Antibiotic resistance: a
rundown of a global crisis. Infect Drug Resist. 2018;11:1645-58. Epub 20181010. doi: 10.2147/idr.S173867. PubMed
PMID: 30349322; PubMed Central PMCID: PMC6188119.

40. Saha K, Kabir ND, Islam MR, Amin MB, Hoque KI, Halder K, et al. Isolation and characterisation of
carbapenem-resistant Pseudomonas aeruginosa from hospital environments in tertiary care hospitals in Dhaka,
Bangladesh. J Glob Antimicrob Resist. 2022;30:31-7. Epub 20220418. doi: 10.1016/j.jgar.2022.04.008. PubMed PMID:
35447383.

41. Gilardi GL. Characterization of Pseudomonas species isolated from clinical specimens. Appl Microbiol.
1971;21(3):414-9. doi: 10.1128/am.21.3.414-419.1971. PubMed PMID: 4928600; PubMed Central PMCID: PMC377195.

42. O'Hara C M. Manual and automated instrumentation for identification of Enterobacteriaceae and other 458 aerobic gram-negative bacilli. Clin Microbiol Rev. 2005;18(1):147-62. doi: 10.1128/cmr.18.1.147-162.2005. PubMed 459 PMID: 15653824; PubMed Central PMCID: PMC544179.

43. Weisburg WG, Barns SM, Pelletier DA, Lane DJ. 16S ribosomal DNA amplification for phylogenetic study. J
Bacteriol. 1991;173(2):697-703. doi: 10.1128/jb.173.2.697-703.1991. PubMed PMID: 1987160; PubMed Central PMCID:
PMC207061.

463 44. Bauer AW, Kirby WM, Sherris JC, Turck M. Antibiotic susceptibility testing by a standardized single disk 464 method. Am J Clin Pathol. 1966;45(4):493-6. PubMed PMID: 5325707.

465 45. Gill MM, Usman J, Kaleem F, Hassan A, Khalid A, Anjum R, et al. Frequency and antibiogram of multi-drug
466 resistant Pseudomonas aeruginosa. J Coll Physicians Surg Pak. 2011;21(9):531-4. PubMed PMID: 21914408.

46. Magiorakos AP, Srinivasan A, Carey RB, Carmeli Y, Falagas ME, Giske CG, et al. Multidrug-resistant,
extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard
definitions for acquired resistance. Clin Microbiol Infect. 2012;18(3):268-81. Epub 20110727. doi: 10.1111/j.14690691.2011.03570.x. PubMed PMID: 21793988.

47. Yong D, Lee K, Yum JH, Shin HB, Rossolini GM, Chong Y. Imipenem-EDTA disk method for differentiation
47. of metallo-beta-lactamase-producing clinical isolates of Pseudomonas spp. and Acinetobacter spp. J Clin Microbiol.
473 2002;40(10):3798-801. doi: 10.1128/jcm.40.10.3798-3801.2002. PubMed PMID: 12354884; PubMed Central PMCID:
474 PMC130862.

475 48. Rad ZR, Rad ZR, Goudarzi H, Goudarzi M, Alizade H, Hematian A, et al. Detection of New Delhi Metallo476 β-lactamase-1 among Pseudomonas aeruginosa isolated from adult and Pediatric patients in Iranian hospitals. Gene
477 Reports. 2021;23:101152. doi: https://doi.org/10.1016/j.genrep.2021.101152.

478 49. Versalovic J, Koeuth T, Lupski JR. Distribution of repetitive DNA sequences in eubacteria and application to
479 fingerprinting of bacterial genomes. Nucleic Acids Res. 1991;19(24):6823-31. doi: 10.1093/nar/19.24.6823. PubMed
480 PMID: 1762913; PubMed Central PMCID: PMC329316.

481 50. Aljindan R, Alsamman K, Elhadi N. ERIC-PCR Genotyping of Acinetobacter baumannii Isolated from
482 Different Clinical Specimens. Saudi J Med Med Sci. 2018;6(1):13-7. Epub 20171214. doi: 10.4103/sjmms.sjmms\_138\_16.
483 PubMed PMID: 30787810; PubMed Central PMCID: PMC6196677.

Kado CI, Liu ST. Rapid procedure for detection and isolation of large and small plasmids. J Bacteriol.
1981;145(3):1365-73. doi: 10.1128/jb.145.3.1365-1373.1981. PubMed PMID: 7009583; PubMed Central PMCID:
PMC217141.

487 52. Macrina FL, Kopecko DJ, Jones KR, Ayers DJ, McCowen SM. A multiple plasmid-containing Escherichia coli
488 strain: convenient source of size reference plasmid molecules. Plasmid. 1978;1(3):417-20. doi: 10.1016/0147489 619x(78)90056-2. PubMed PMID: 372973.

490 53. Haider K, Huq MI, Talukder KA, Ahmad QS. Electropherotyping of plasmid DNA of different serotypes of
491 Shigella flexneri isolated in Bangladesh. Epidemiol Infect. 1989;102(3):421-8. doi: 10.1017/s0950268800030132. PubMed
492 PMID: 2661251; PubMed Central PMCID: PMC2249461.

- 493
- 494
- 405
- 495
- 496
- 497
- 498
- 499
- 500
- 501

	Primer	Sequence (5'-3')	Amplicon size (bp)	Annealing Temperature (°C)	Reference
	bla-IMP	F- GGA ATA GAG TGG CTT AAT TCT C	188	52	[24]
		R- CCA AAC CAC TAC GTT ATC T			
	bla-VIM	F- GAT GGT GTT TGG TCG CAT A	390	52	[24]
		R- CGA ATG CGC AGC ACC AG			
	bla-SPM	F- AAA ATC TGG GTA CGC AAA CG	271	52	[24]
		R- ACA TTA TCC GCT GGA ACA GG			
	bla-NDM-1	F- CCT ACA ATC TAA CGG CGA CC	621	56	[48]
		R- TCG CCG TGT CCA GGT ATA AC			
	ERIC2	AAG TAA GTG ACT GGG GTG AGC G		48	[49]
503					
504					
505					
506					
507					
508					
509					
510					

## 502 Table 1. List of PCR primers used in this study.

## **Table 2. Collection of samples and culture results**

Sample type	Samples co EMCH	ollected from	Samples co GMCH	llected from	Total samples	Total P. aeruginosa isolates
	Sample number	Positive for <i>P</i> . aeruginosa	Sample Positive for <i>P</i> . number <i>aeruginosa</i>			
Urine	72 (62%)	16 (22%)	43 (38%)	7 (16%)	115	23
Urinary Catheter	7 (58%)	4 (57%)	5 (42%)	1 (20%)	12	5
Sec. wound infection	12 (57%)	7 (58%)	9 (43%)	4 (45%)	21	11
Pus	37 (54%)	5 (13%)	32 (46%)	5 (15%)	69	10
Burn wound	8 (80%)	2 (25%)	2 (20%)	0	10	2
Blood	9 (100%)	1 (11%)	0	0	9	1
Tracheal aspirate	2 (100%)	1 (50%)	0	0	2	1
Total	147 (62%)	36 (24%)	91 (38%)	17 (19%)	238	53

518 Here, GMCH = Gonoshasthaya Samaj Vittik Medical College & Hospital; EMCH =

519 Enam Medical College & Hospital.

# Table 3. Antibiotic susceptibility and resistance determinants in Imipenem-resistant clinical *P. aeruginosa*

Isolate ID	late Specimen MIC Value (Hospital)		Phenotypic Detection of MBL Production		Presence of MBL gene				Plasmid (MDa)	
	(100) 100)	(µg/ml)	IMP (Zone, mm)	IMP+ EDTA (Zone, mm)	Interpretation	bla- IMP	bla- VIM	bla- SPM	bla- NDM1	-
PA01 <sup>a</sup>	Reference	0.5	19	20	Negative	-	-	-	-	-
PU1	Urine (A)	8	0	0	Negative	-	-	-	-	-
PU5	Urine (A)	8	0	14	Negative	-	-	-	-	-
PU6	Urine (A)	8	0	15	Intermediate	-	-	-	_	-
PUS1	Cath. Swb (A)	8	0	15	Intermediate	-	-	-	_	-
PS1	Wound Swb (A)	16	0	16	Intermediate	-	-	-	-	-
PS2	Wound Swb (A)	8	0	15	Intermediate	-	-	-	-	-
PU17	Urine (B)	128	0	22	Positive	-	-	-	+	0.5
PU26	Urine (B)	8	0	20	Positive	-	+	-	-	1.2
PWS12	Wound Swb (B)	32	0	20	Positive	-	+	-	-	-
PWS17	Cath. Swb (B)	128	0	24	Positive	-	-	-	+	0.5, 1.2
PWS18	Cath. Swb (B)	128	0	21	Positive	-	-	-	+	0.5, 1.2
PWS21	Wound Swb (B)	128	0	24	Positive	-	+	-	-	0.2, 1.2
PWS22	Wound Swb (B)	16	0	22	Positive	-	+	-	-	0.2, 1.2
PWS23	Wound Swb (B)	16	0	16	Intermediate	-	+	-	-	-
PWS25	Cath. Swb (B)	8	0	16	Intermediate	-	+	-	-	0.2, 1.2
PWS26	Tracheal Asp (B)	128	0	23	Positive	-	+	-	-	-

<sup>534</sup> Here, '+' denotes positive; '-' denotes negative; IMP= Imipenem; A= Gonoshasthaya Samaj Vittik Medical

<sup>535</sup> College & Hospital (GMCH); B= Enam Medical College & Hospital (EMCH). Cath. Swb= Catheter Swab;



**Figure 1. PCR based detection of MBL variants.** MBL gene sequences were PCR amplified using the variant-specific primers (Table 3). PCR products were electrophoresed through 1% agaroge gels, stained with ethidium bromide, and visualized with UV light. The 100 bp DNA ladder indicates the size of PCR products. Lane 2, 7, 12 and 16 represent variant-specific positive controls, and lane 3, 8, 13 and 17 represent negative controls. No isolates were positive in *bla*-IMP and *bla*-SPM specific PCR.

554



#### 555

Figure 2. UPGMA cluster analysis of ERIC-PCR results: A). ERIC-PCR products were 556 electrophoresed on 1% agarose gel, stained with ethidium bromide, and visualized on 557 UV light. Lane 1 represent 100 bp DNA ladder; Lane 8 and 9 represent isolates PWS18 558 and PWS17 respectively showing identical amplification pattern. Similarly, Lane 10 and 559 11 represent isolates PWS22 and PWS21 respectively showing identical amplification. 560 Rest of the lanes represent unique PCR amplification profiles. B). Dendrogram based on 561 UPGMA cluster analysis of ERIC-PCR results; the names of the analyzed strains are 562 mentioned with their phylogenetic groups denominated as Cluster I, II and III. 563 564



**Figure 1. PCR based detection of MBL variants.** MBL gene sequences were PCR amplified using the variant-specific primers (Table 3). PCR products were electrophoresed through 1% agaroge gels, stained with ethidium bromide, and visualized with UV light. The 100 bp DNA ladder indicates the size of PCR products. Lane 2, 7, 12 and 16 represent variant-specific positive controls, and lane 3, 8, 13 and 17 represent negative controls. No isolates were positive in *bla*-IMP and *bla*-SPM specific PCR.



**Figure 2. UPGMA cluster analysis of ERIC-PCR results:** A). ERIC-PCR products were electrophoresed on 1% agarose gel, stained with ethidium bromide, and visualized on UV light. Lane 1 represent 100 bp DNA ladder; Lane 8 and 9 represent isolates PWS18 and PWS17 respectively showing identical amplification pattern. Similarly, Lane 10 and 11 represent isolates PWS22 and PWS21 respectively showing identical amplification. Rest of the lanes represent unique PCR amplification profiles. B). Dendrogram based on UPGMA cluster analysis of ERIC-PCR results; the names of the analyzed strains are mentioned with their phylogenetic groups denominated as Cluster I, II and III.

Primer	Sequence (5'-3')	Amplicon size (bp)	Annealing Temperature (°C)	Reference
bla-IMP	F- GGA ATA GAG TGG CTT AAT TCT C	188	52	[24]
	R- CCA AAC CAC TAC GTT ATC T			
bla-VIM	F- GAT GGT GTT TGG TCG CAT A	390	52	[24]
	R- CGA ATG CGC AGC ACC AG			
bla-SPM	F- AAA ATC TGG GTA CGC AAA CG	271	52	[24]
	R- ACA TTA TCC GCT GGA ACA GG			
bla-NDM-1	F- CCT ACA ATC TAA CGG CGA CC	621	56	[48]
	R- TCG CCG TGT CCA GGT ATA AC			
ERIC2	AAG TAA GTG ACT GGG GTG AGC G		48	[49]

#### Table 1. List of PCR primers used in this study.

#### Table 2. Collection of samples and culture results

Sample type	Samples coll	ected from EMCH	Samples colle	cted from GMCH	Total samples	Total P. aeruginosa isolates	
	Sample number	Positive for <i>P.</i> aeruginosa	Sample number	Positive for <i>P.</i> aeruginosa			
Urine	72 (62%)	16 (22%)	43 (38%)	7 (16%)	115	23	
Urinary Catheter	7 (58%)	4 (57%)	5 (42%)	1 (20%)	12	5	
Sec. wound infection	12 (57%)	7 (58%)	9 (43%)	4 (45%)	21	11	
Pus	37 (54%)	5 (13%)	32 (46%)	5 (15%)	69	10	
Burn wound	8 (80%)	2 (25%)	2 (20%)	0	10	2	
Blood	9 (100%)	1 (11%)	0	0	9	1	
Tracheal aspirate	2 (100%)	1 (50%)	0	0	2	1	
Total	147 (62%)	36 (24%)	91 (38%)	17 (19%)	238	53	

Here, GMCH = Gonoshasthaya Samaj Vittik Medical College & Hospital; EMCH = Enam Medical College & Hospital.

## Table 3. Antibiotic susceptibility and resistance determinants in Imipenem-resistant clinical P. aeruginosa

Isolate	Specimen	MIC	Phenotyp	ic Detectior	n of MBL Production	Presence of MBL gene				Plasmid	
	(Hospital)	(Hospital) (μg/ml)	(μg/ml)	IMP (Zone, mm)	IMP+ EDTA (Zone, mm)	Interpretation	bla- IMP	bla- VIM	bla- SPM	bla- NDM1	ַ (ויעטא)
PA01 <sup>a</sup>	Reference	0.5	19	20	Negative	_	-	_	-	-	
PU1	Urine (A)	8	0	0	Negative	-	-	-	-	_	
PU5	Urine (A)	8	0	14	Negative	-	-	-	-	-	
PU6	Urine (A)	8	0	15	Intermediate	-	-	-	-	-	
PUS1	Cath. Swb (A)	8	0	15	Intermediate	-	-	-	-	-	
PS1	Wound Swb (A)	16	0	16	Intermediate	-	-	-	-	-	
PS2	Wound Swb (A)	8	0	15	Intermediate	-	-	-	-	-	
PU17	Urine (B)	128	0	22	Positive	-	-	-	+	0.5	
PU26	Urine (B)	8	0	20	Positive	-	+	-	-	1.2	
PWS12	Wound Swb (B)	32	0	20	Positive	-	+	-	-	-	
PWS17	Cath. Swb (B)	128	0	24	Positive	-	-	-	+	0.5, 1.2	
PWS18	Cath. Swb (B)	128	0	21	Positive	-	-	-	+	0.5, 1.2	
PWS21	Wound Swb (B)	128	0	24	Positive	-	+	-	-	0.2, 1.2	
PWS22	Wound Swb (B)	16	0	22	Positive	-	+	-	-	0.2, 1.2	
PWS23	Wound Swb (B)	16	0	16	Intermediate	-	+	-	-	-	
PWS25	Cath. Swb (B)	8	0	16	Intermediate	-	+	-	-	0.2, 1.2	
PWS26	Tracheal Asp (B)	128	0	23	Positive	-	+	-	-	-	

Here, '+' denotes positive; '-' denotes negative; IMP= Imipenem; A= Gonoshasthaya Samaj Vittik Medical College & Hospital (GMCH); B= Enam Medical College & Hospital (EMCH). Cath. Swb= Catheter Swab; Wound Swb= Secondary Wound Swab; Tracheal Asp= Tracheal Aspirate

 $^{a}$ PAO1: Reference strain in susceptibility testing and  $\beta$ -lactamase assays (NCBI: txid208964).